You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

  • Authors: Ajai Chari, MD; Ajay Nooka, MD, MPH, FACP; Krina Patel, MD, MSc
  • CME / ABIM MOC / CE Released: 12/27/2022
  • Valid for credit through: 12/27/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (1.5 contact hours are in the area of pharmacology)

    Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists and other healthcare providers involved in the care of patients with MM.

The goal of this activity is for learners to be better able to implement modern, multidrug regimens for patients with newly diagnosed and relapsed/refractory (R/R) MM, with a goal of improving patient outcomes.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Available clinical data for triplet and quadruplet drug regimens in patients with MM
    • Strategies to manage adverse events with multidrug regimens in MM
  • Have greater competence related to
    • Selecting multidrug combination therapy according to patient and disease considerations
  • Demonstrate greater confidence in their ability to
    • Apply the latest data from clinical trials to their practices to optimize patient outcomes


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Ajai Chari, MD

    Professor of Medicine
    Director of Clinical Research
    Multiple Myeloma Program
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Disclosures

    Ajai Chari, MD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; Bristol Myers Squibb Company; Celgene; Millennium/Takeda; Janssen; Karyopharm Therapeutics; Sanofi; Seagen Inc.
    Research funding from: Amgen; Array Biopharma; Celgene; GlaxoSmithKline; Janssen; Millennium/Takeda; Novartis Pharmaceuticals; Oncoceutics; Pharmacyclics; Seagen Inc.

Panelists

  • Ajay Nooka, MD, MPH, FACP

    Professor
    Department of Hematology and Medical Oncology
    Medical Director
    Winship Data and Technology Applications Shared Resource
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Dr Nooka and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Nooka’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Ajay Nooka, MD, MPH, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Adaptive; Amgen; Beyond Spring; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Legend; Oncopeptides; Sanofi; SecuraBio; Takeda
    Research funding from: Amgen; Arch Oncology; Bristol Myers Squibb Company; Genentech; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; KITE; Takeda

  • Krina Patel, MD, MSc

    Associate Professor
    Center Medical Director
    Department of Lymphoma/Myeloma
    Division of Cancer Medicine
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Krina Patel, MD, MSc, has the following relevant financial relationships:
    Consultant or advisor for: Arcellx; Bristol Myers Squibb Company; Celgene; Cellectis; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer
    Contracted researcher for: Allogene; Bristol Myers Squibb Company; Celgene; Cellectis; Nektar; Precision Bio; Takeda

Editor

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC

    Disclosures

    Megan Whitney, DMD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-23-037-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

Authors: Ajai Chari, MD; Ajay Nooka, MD, MPH, FACP; Krina Patel, MD, MScFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/27/2022

Valid for credit through: 12/27/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to implement modern, multidrug regimens for patients with newly diagnosed and R/R MM, with a goal of improving patient outcomes.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print